A Proof-of-Concept Study of Minocycline in Autism

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Autism Spectrum DisorderAutism
Interventions
DRUG

Minocycline

Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.

DRUG

Placebos

Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.

Trial Locations (3)

15203

Center for Autism and Developmental Disorders - University of Pittsburgh Medical Center, Pittsburgh

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

65211

Thompson Center for Autism & Neurodevelopmental Disorders - University of Missouri, Columbia

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT04031755 - A Proof-of-Concept Study of Minocycline in Autism | Biotech Hunter | Biotech Hunter